BioAge Labs (NASDAQ: BIOA) holder files to sell 233,107 shares

Rhea-AI Filing Summary

A holder of BioAge Labs, Inc. common stock has filed a notice under Rule 144 to sell 233,107 shares of common stock through Raymond James & Associates on the NASDAQ, with an approximate sale date of 01/13/2026. The filing lists an aggregate market value of these planned sales of $4,195,926.00 and states that 35,855,037 shares of the issuer’s common stock are outstanding.

The shares to be sold relate to a prior restricted stock purchase dated 08/14/2015, when 1,210,056 common shares were acquired from BioAge Labs, Inc. and paid for by check. By signing the notice, the person for whose account the securities are to be sold represents that they do not know of any material adverse information about the issuer’s operations that has not been publicly disclosed.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
COMMON	RAYMOND JAMES & ASSOCIATES 880 CARILLON PARKWAY ST. PETERSBURG FL 33716	233107	4195926.00	35855037	01/13/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
COMMON	08/14/2015	RESTRICTED STOCK PURCHASE	BIOAGE LABS, INC			1210056	08/14/2015	CHECK

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

How many BioAge Labs (BIOA) shares are covered by this Rule 144 notice?

The notice covers the planned sale of 233,107 shares of BioAge Labs, Inc. common stock.

What is the aggregate market value of the BioAge Labs (BIOA) shares to be sold?

The filing reports an aggregate market value of $4,195,926.00 for the 233,107 common shares to be sold.

On which exchange and through which broker will the BioAge Labs (BIOA) shares be sold?

The shares are expected to be sold on the NASDAQ through Raymond James & Associates, located at 880 Carillon Parkway, St. Petersburg, FL 33716.

When is the approximate sale date for the BioAge Labs (BIOA) shares in this filing?

The approximate date of sale listed in the notice is 01/13/2026.

How many BioAge Labs (BIOA) common shares are outstanding according to the notice?

The notice states that 35,855,037 shares of BioAge Labs, Inc. common stock are outstanding.

How and when were the BioAge Labs (BIOA) shares originally acquired?

The securities to be sold were acquired as common stock in a restricted stock purchase on 08/14/2015, when 1,210,056 shares were obtained from BioAge Labs, Inc. and paid for by check.

What representation does the selling person make in this BioAge Labs (BIOA) notice?

By signing, the person for whose account the securities are to be sold represents that they do not know any material adverse information about the issuer’s current or prospective operations that has not been publicly disclosed.